Lansoprazole and Epclusa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lansoprazole (lansoprazole) and Epclusa (sofosbuvir; velpatasvir). Common drug interactions include atrial fibrillation among females and hepatic encephalopathy among males.

The phase IV clinical study analyzes what interactions people have when they take Lansoprazole and Epclusa. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Lansoprazole?

Lansoprazole has active ingredients of lansoprazole. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 129,663 Lansoprazole users. Check the latest studies of Lansoprazole.

What is Epclusa?

Epclusa has active ingredients of sofosbuvir; velpatasvir. eHealthMe is studying from 12,120 Epclusa users. Check the latest studies of Epclusa.



On Jul, 27, 2026

17 people who take Lansoprazole and Epclusa together, and have interactions are studied.

Lansoprazole and Epclusa drug interactions.

What are the common drug interactions of Lansoprazole and Epclusa, by gender? *:

female:

  1. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  2. Hepatic failure (liver failure)
  3. Bradycardia (abnormally slow heart action)
  4. Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
  5. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  6. Blood potassium increased
  7. Dehydration (dryness resulting from the removal of water)
  8. Dyspnoea (difficult or laboured respiration)
  9. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  10. Varicose vein (veins that have become enlarged and tortuous)

male:

  1. Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
  2. Hepatic failure (liver failure)
  3. Dysuria (painful or difficult urination)
  4. Emotional distress
  5. Fatigue (feeling of tiredness)
  6. Nephrolithiasis (calculi in the kidneys)
  7. Osteonecrosis (death of bone)
  8. Pain
  9. Renal failure (kidney dysfunction)
  10. Tooth loss

What are the common drug interactions of Lansoprazole and Epclusa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Hepatic failure (liver failure)
  2. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  3. Anxiety
  4. Bone density decreased
  5. Bone loss
  6. Chronic kidney disease
  7. Dysuria (painful or difficult urination)
  8. Emotional distress
  9. Fatigue (feeling of tiredness)
  10. Nephrolithiasis (calculi in the kidneys)

60+:

  1. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  2. Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
  3. Renal impairment (severely reduced kidney function)
  4. Hepatic failure (liver failure)
  5. Ascites (accumulation of fluid in the abdominal cavity)
  6. Bradycardia (abnormally slow heart action)
  7. Cerebellar haemorrhage (bleeding in cerebeller)
  8. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  9. Dyspnoea (difficult or laboured respiration)
  10. Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)

What are the existing conditions these people have? *

  1. Hepatitis C: 11 people, 64.71%
  2. Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 9 people, 52.94%
  3. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 11.76%
  4. Hiv Infection: 2 people, 11.76%
  5. Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 2 people, 11.76%
  6. Hepatic Function Abnormal: 1 person, 5.88%
  7. Cardiac Failure: 1 person, 5.88%
  8. Diabetes: 1 person, 5.88%
  9. Gastric Ulcer (stomach ulcer): 1 person, 5.88%
  10. Gastritis - Chronic (long lasting inflammation of stomach): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Lansoprazole and Epclusa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lansoprazole and Epclusa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lansoprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Epclusa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lansoprazole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Epclusa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on lansoprazole and sofosbuvir; velpatasvir (the active ingredients of Lansoprazole and Epclusa, respectively), and Lansoprazole and Epclusa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: